#&'$**)$"')*)""')*'*&)& >:?3 T+@T9::09?3

SPECIAL   

2016 AAFP Guidelines for the Management of Feline Hyperthyroidism

Hazel C Carney DVM MS DABVP (Canine/Feline) Co-Chair WestVet Emergency and Specialty Center, 5019 North Sawyer Avenue, Garden City, ID 83617, USA Email: [email protected] Cynthia R Ward VMD PhD DACVIM Co-Chair University of Georgia, College of Veterinary Medicine, 2200 College Station Road, Athens, GA 30605, USA Email: [email protected] Steven J Bailey DVM DABVP (Feline) Exclusively Cats Veterinary Hospital, 6650 Highland Road, Ste 116, Waterford, MI 48327, USA David Bruyette DVM DACVIM VCA West Los Angeles Animal Hospital, 1900 South Sepulveda Blvd, Los Angeles, CA 90025, USA Sonnya Dennis DVM DABVP (Canine/Feline) Stratham-Newfields Veterinary Hospital, 8 Main Street, Newfields, NH 03856, USA Duncan Ferguson VMD PhD DACVIM DACVCP College of Veterinary Medicine – University of Illinois, Department of Comparative Biosciences, 3840 Veterinary Medicine Basic Sciences Bldg, 2001 South Lincoln Avenue, Urbana, IL 61802, USA Amy Hinc VMD DABVP (Feline) Cosmic Cat Veterinary Clinic, 220 East Main Street, Branford, CT 06405, USA A Renee Rucinsky DVM DABVP (Feline) Mid Atlantic Cat Hospital, 201 Grange Hall Road, Queenstown, MD 21658, USA

400

Clinical context: Since 1979 and 1980 when the first reports of clinical feline hyperthyroidism (FHT) appeared in the literature, our understanding of the disease has evolved tremendously. Initially, FHT was a disease that only referral clinicians treated. Now it is a disease that primary clinicians routinely manage. Inclusion of the measurement of total thyroxine concentration in senior wellness panels, as well as in diagnostic work-ups for sick cats, now enables diagnosis of the condition long before the cat becomes the classic scrawny, unkempt, agitated patient with a bulge in its neck. However, earlier recognition of the problem has given rise to several related questions: how to recognize the health significance of the early presentations of the disease; how early to treat the disease; whether to treat FHT when comorbid conditions are present; and how to manage comorbid conditions such as chronic kidney disease and cardiac disease with treatment of FHT. The 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism (hereafter referred to as the Guidelines) will shed light on these questions for the general practitioner and suggest when referral may benefit the cat. Scope: The Guidelines explain FHT as a primary disease process with compounding factors, and provide a concise explanation of what we know to be true about the etiology and pathogenesis of the disease. The Guidelines also: < Distill the current research literature into simple recommendations for testing sequences that will avoid misdiagnosis and separate an FHT diagnosis into six clinical categories with associated management strategies. < Emphasize the importance of treating all hyperthyroid cats, regardless of comorbidities, and outline the currently available treatments for the disease. < Explain how to monitor the treated cat to help avoid exacerbating comorbid diseases. < Dispel some of the myths surrounding certain aspects of FHT and replace them with an evidence-based narrative that veterinarians and their practice teams can apply to feline patients and communicate to their owners. Evidence base: To help ensure better case outcomes, the Guidelines reflect currently available, evidenced-based knowledge. If research is lacking, or if a consensus does not exist, the expert panel of authors has made recommendations based on their extensive, cumulative clinical experience.

Feline hyperthyroidism: an overview (SKQNST IEDSMRIEMOQJQLGT (-7 T CQMLRT 2 &BSTIPLTKONB +FDDKSGSNRPRQONT ;QRIT KS=ORIE1 MOQNST JFMQNBT RIQLT DSMQOJT ;QKKT MSLOK=ST QPRMO1 BSNQHT IEDORIEMOQJQLGT PNJT GPET TTT-OK!;OMRIT #@T 7ISMPNT %@T 'PMDSNRSMT #@T SRT PKAT 73A=@:7=?B9B;6C B> @:A 8C8C88AC 4?=C 9B44A=B>0C B>8B/ 9A>8A;C ?4C 4A5B>AC :73A=@:7=?B9B;6C B>C ?>9?>C  C 9C 31 %MOHSSJQNBLT OCT RIST ?8RIT $'*.1'&T HONBMSLL,T >::8T +SDRT ?06, KPLBO;@TDT>>:A 5 TTT+PLLNPFTAT(3B9A6B?5?0B8CB>.A;@B0C?>C@:AC3=A.8AC?4C4A5B>A :73A=@:7=?B9B;6CB>CC2=,C3?325CB>CA=671C")&&
($*& %**$)"'(")&)* )"!(")&) >::3,T69/T98:0982A ?: [email protected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email protected]=9?6B#A9 8?63C?4CB>@=?2;C.A=;2;C;2,82@A?2;CB;@=C?4 =AC4?=C@=A@C?4C:73A=@:7=?B9B;6CB>C82/T888A 2> TFHET#@T%SRSMLONT.$@TPNJOKDIT#@TSRTPKAT(44B84?=6C 9B80??4A 4: T7MSDPNQSMT &@T %SRSMLONT .$T PNJT &FHOQNT "%AT "::?3,T?4/T5>0?:6A 46 TQNR!SMT %%AT ?>;B9A=;C B>C @:AC @=A@C ?4C 4A5B>AC :73A=@:7/ =?B9B;61 )(*$"'*&(*%!*!$$*%'"!*&( ?559,T>9/T8220848A 49 T-QKKT$@TQSLSBT.&@TQNBL8AC ?4C 3=?,5A6;CB2A;C?4C,B553A 42 T(KPNJSMLT#&TPNJT-PM=SET-#ATA5B>AC@:7=?B9A8@?67)C56A 5: Tmail protected](SMBFLONT"'AT%:7=?B9C:?=6?>AC6A@@/?->A9C8